Standard BioTools Amends 8-K, Confirms Nasdaq Listing for LAB Stock
Ticker: LAB · Form: 8-K/A · Filed: Jan 19, 2024 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K/A |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative-update, exchange-listing, 8-ka
TL;DR
**Standard BioTools (LAB) filed an 8-K/A, confirming its Nasdaq listing and stock details.**
AI Summary
Standard BioTools Inc. filed an 8-K/A on January 19, 2024, amending a previous report from January 4, 2024. This filing primarily serves to update the company's registration information, confirming its common stock, with a par value of $0.001 per share, is traded under the symbol 'LAB' on the Nasdaq Global Select Market. This matters to investors as it reaffirms the company's listing status and provides updated administrative details, ensuring transparency regarding its publicly traded securities.
Why It Matters
This filing confirms Standard BioTools' continued listing on the Nasdaq Global Select Market, providing clarity and stability for investors regarding where their shares are traded.
Risk Assessment
Risk Level: low — This filing is an administrative update and does not indicate any new financial or operational risks for the company.
Analyst Insight
Investors should note this filing as a routine administrative update confirming the company's stock exchange listing, but it does not provide new information that would warrant immediate trading action.
Key Numbers
- $0.001 — Par value per share (This is the stated par value of Standard BioTools Inc.'s common stock.)
Key Players & Entities
- Standard BioTools Inc. (company) — the registrant filing the 8-K/A
- LAB (company) — the trading symbol for Standard BioTools Inc. common stock
- Nasdaq Global Select Market (company) — the exchange where Standard BioTools Inc. common stock is registered
- $0.001 (dollar_amount) — the par value per share of common stock
- January 4, 2024 (date) — the date of the earliest event reported in the original 8-K
- January 19, 2024 (date) — the filing date of the 8-K/A
Forward-Looking Statements
- Standard BioTools Inc. will maintain its listing on the Nasdaq Global Select Market. (Standard BioTools Inc.) — high confidence, target: Ongoing
FAQ
What is the purpose of this 8-K/A filing by Standard BioTools Inc.?
The 8-K/A filing by Standard BioTools Inc. is an amendment to a previous report, primarily to update and confirm the company's registration information, specifically that its common stock is registered on the Nasdaq Global Select Market under the trading symbol 'LAB'.
What is the trading symbol and par value of Standard BioTools Inc.'s common stock?
Standard BioTools Inc.'s common stock trades under the symbol 'LAB' and has a par value of $0.001 per share, as stated in the filing.
On which exchange is Standard BioTools Inc.'s common stock registered?
The filing explicitly states that Standard BioTools Inc.'s common stock is registered on the Nasdaq Global Select Market.
What was the date of the earliest event reported in the original 8-K that this filing amends?
The date of the earliest event reported in the original 8-K was January 4, 2024, as indicated in the 'Date of report (Date of earliest event reported)' section.
What is the business address of Standard BioTools Inc. as listed in the filing?
The business address of Standard BioTools Inc. is 2 Tower Place, Suite 2000, South San Francisco, California 94080, with a business phone number of (650) 266-6000.
Filing Stats: 743 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2024-01-19 16:33:24
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share LAB Nasdaq Global Select Ma
Filing Documents
- tm243472d1_8ka.htm (8-K/A) — 29KB
- tm243472d1_ex23-1.htm (EX-23.1) — 10KB
- tm243472d1_ex99-1.htm (EX-99.1) — 642KB
- tm243472d1_ex99-2.htm (EX-99.2) — 548KB
- tm243472d1_ex99-3.htm (EX-99.3) — 355KB
- 0001104659-24-005246.txt ( ) — 1919KB
- lab-20240104.xsd (EX-101.SCH) — 3KB
- lab-20240104_lab.xml (EX-101.LAB) — 33KB
- lab-20240104_pre.xml (EX-101.PRE) — 22KB
- tm243472d1_8ka_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The audited consolidated financial statements of SomaLogic as of and for the years ended December 31, 2022 and 2021 and the unaudited consolidated financial statements of SomaLogic as of and for the nine months ended September 30, 2023 and September 30, 2022 are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 9.01 by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined financial statements for the year ended December 31, 2022 and as of and for the nine months ended September 30, 2023 giving effect to the acquisition of SomaLogic are filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated in this Item 9.01 by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. 99.1 Audited consolidated financial statements of SomaLogic, Inc. as of and for the years ended December 31, 2022 and 2021. 99.2 Unaudited Condensed Consolidated Financial Statements of Operations of SomaLogic, Inc., as of and for the nine months ended September 30, 2023 and September 30, 2022. 99.3 Unaudited Pro Forma Condensed Combined Financial Statements of Standard BioTools Inc. and SomaLogic, Inc. for the year ended December 31, 2022 and as of and for the nine months ended September 30, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 19, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer